The Effects of Diet, Sulfonylurea, and Repaglinide Therapy on Clinical and Metabolic Parameters in Type 2 Diabetic Patients During Ramadan
- 1 January 2004
- journal article
- clinical trial
- Published by Taylor & Francis Ltd in Endocrine Research
- Vol. 30 (2), 169-177
- https://doi.org/10.1081/erc-200027375
Abstract
Background and Aim: Diabetes and its treatment can cause problems for the Muslim population. The aim of this study was to evaluate the effect of different therapy models on clinical and metabolic status in type 2 diabetic patients during Ramadan. Material and Methods: Fifty‐two type 2 diabetic patients were included to this study. Twelve of patients were on diabetic diet only before and during Ramadan (Group 1). Forty of patients had had sulfonylurea (Glimepiride 23 patients, gliclazide 17 patients) before Ramadan. Thirteen of these patients were on a single dose sulfonylurea (Glimepiride 8 patients, gliclazide 5 patients) (Group 2) and 27 were on Repaglinide 2 × 2 mg (Group 3) during Ramadan. β‐Hydroxybutyric acid, glucose, fructosamine, HbA1c, lipid levels and body weight were measured before and after Ramadan. Results: Body weight, fasting plasma glucose, fructosamine, HbA1c, total cholesterol were not changed in groups during the study. Triglyceride level decreased after Ramadan in groups 2 (p = 0.002) and 3 (p = 0.024). HDL‐cholesterol level increased in group 3 (p = 0.022). Fasting capillary β‐hydroxybutyric acid level increased in group 1 (p = 0.034) and didn't change in groups 2 and 3 during the Ramadan. Only one hypoglycemic event occurred at day 6 of Ramadan in patients in group 2 (the patient was on 3 mg glimepiride). Conclusion: Our results conclude that Ramadan fasting affects metabolic parameters in type 2 diabetes and hypoglycemia should be kept in mind especially in patients using sulfonylurea treatment. Ramadan fasting is not advised for type 2 diabetics while taking medical therapy. If the patient wants Ramadan fasting, these patients using Repaglinide can reduce the frequency of hypoglycemia.Keywords
This publication has 16 references indexed in Scilit:
- Repaglinide versus glibenclamide treatment of Type 2 diabetes during Ramadan fastingDiabetes Research and Clinical Practice, 2002
- Repaglinide improves blood glucose control in sulphonylurea-naive type 2 diabetesDiabetes Research and Clinical Practice, 2001
- Flexible prandial glucose regulation with repaglinide in patients with Type 2 diabetesDiabetes Research and Clinical Practice, 1999
- A comparison of repaglinide and glibenclamide in the treatment of type 2 diabetic patients previously treated with sulphonylureas.European Journal of Clinical Pharmacology, 1999
- The emerging role of post-prandial hyperglycaemic spikes in the pathogenesis of diabetic complicationsDiabetic Medicine, 1998
- IntroductionPractical Diabetes International, 1998
- Muslims with non-insulin dependent diabetes fasting during Ramadan: treatment with glibenclamide.BMJ, 1993
- Postprandial triglyceride response in Type 1 (insulin-dependent) diabetes mellitus is not altered by short-term deterioration in glycaemic control or level of postprandial insulin replacementDiabetologia, 1991
- Effects of fasting during Ramadan on urinary excretion in Malaysian MuslimsBritish Journal of Nutrition, 1990
- Diabetes Mellitus and Ramadan Fasting: The Need for a Critical AppraisalDiabetic Medicine, 1988